Daily Sepsis Research Analysis
Three impactful sepsis studies stood out today: a comprehensive meta-analysis shows current rapid molecular assays lack sufficient sensitivity to replace blood culture; longitudinal lymphocyte trajectory phenotyping predicts 28-day mortality and enables precision risk stratification; and a secondary analysis of CLOVERS suggests initial lactated Ringer’s may improve survival versus normal saline in sepsis-induced hypotension.
Summary
Three impactful sepsis studies stood out today: a comprehensive meta-analysis shows current rapid molecular assays lack sufficient sensitivity to replace blood culture; longitudinal lymphocyte trajectory phenotyping predicts 28-day mortality and enables precision risk stratification; and a secondary analysis of CLOVERS suggests initial lactated Ringer’s may improve survival versus normal saline in sepsis-induced hypotension.
Research Themes
- Rapid diagnostics and the role of molecular assays in bloodstream infection
- Immune trajectory phenotyping for precision prognostication in sepsis
- Fluid resuscitation strategies: balanced crystalloids versus normal saline
Selected Articles
1. Rapid molecular assays versus blood culture for bloodstream infections: a systematic review and meta-analysis.
Across 75 studies, rapid molecular assays had high specificity but only moderate sensitivity versus blood culture (patient-level sensitivity 0.659), with wide variation across platforms. The authors conclude RMAs should not replace blood culture but can serve as add-on tests to increase pathogen detection, calling for higher-sensitivity assays and better implementation studies.
Impact: This comprehensive, pre-registered meta-analysis synthesizes diagnostic performance across commercial platforms and sets realistic expectations for their role in sepsis workups.
Clinical Implications: Use RMAs as adjuncts to blood culture to accelerate organism identification while recognizing false negatives; do not discontinue cultures. Prioritize platforms with higher sensitivity where available and consider larger blood volumes.
Key Findings
- Pooled patient-level specificity was 0.858 (95% CI 0.830–0.883) and sensitivity was 0.659 (95% CI 0.594–0.719) versus blood culture.
- Sensitivity varied substantially by platform (e.g., IRIDICA 0.783; MagicPlex 0.492), and specificity varied by care setting (lower in ICU than ED).
- Given low sensitivity, RMAs cannot replace blood culture but may increase pathogen detection as add-on tests; higher-sensitivity designs and larger blood volumes are needed.
Methodological Strengths
- Prospero-registered systematic review with comprehensive multi-database search and QUADAS-2/QUADAS-C bias assessment
- Bivariate modeling with stratified analyses by unit-of-analysis, platform, and care setting
Limitations
- High risk of bias across included studies and substantial heterogeneity between platforms and settings
- Use of blood culture as imperfect reference standard and limited standardized reporting across studies
Future Directions: Develop higher-sensitivity, broader-coverage RMAs using larger blood volumes; conduct pragmatic implementation studies with standardized endpoints to quantify time-to-targeted-therapy benefits.
BACKGROUND: Timely management of sepsis with early targeted antimicrobial therapy improves patient outcomes. Rapid molecular assays (RMAs) have emerged, enabling the detection of bloodstream infection (BSI) with a shorter turnaround time than blood cultures (BCs). The accuracy of several RMAs has not been comprehensively reviewed. We aimed to identify commercial RMAs reported in the literature and evaluate their diagnostic performance compared to BC. METHODS: A systematic review and meta-analysis was conducted, covering MEDLINE, Cochrane Library, Embase, and Web of Science from inception to September 23, 2024. Eligible studies included patients with suspected or documented BSI, tested with both an RMA (turnaround time of ≤12 h, targeting ≥20 pathogens) and BC. Non-original research articles and animal studies were excluded. The primary outcomes were pooled sensitivity and specificity of RMAs for pathogen detection compared to BC. Bivariate analysis was used to produce summary receiver operating characteristic plots and diagnostic metric measures stratified by different units of analysis (sample versus patient), RMA types, and patient populations. Risk of bias was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) and Quality Assessment of Diagnostic Accuracy Studies-Comparative (QUADAS-C) tools. The study was registered with PROSPERO, CRD42022377280. FINDINGS: A total of 63,916 articles were identified, of which 104 were included in the qualitative synthesis and 75 in the quantitative synthesis, covering 17,952 samples and 11,393 patients analyzed separately. Eleven RMAs were identified, with four included in the RMA-based subgroup analysis (LightCycler SeptiFast Test MGRADE®, IRIDICA BAC BSI assay, SepsiTest, MagicPlex Sepsis Test) and five additional ones in the pooled analysis (UMD-SelectNA, VYOO®, MicrobScan assay, MicrobScan-Kairos24/7, REBA Sepsis-ID test). Two RMAs were included in the qualitative synthesis only (InfectID-BSI, Pilot Gene Technology droplet digital polymerase chain reaction). Pooled specificity of RMAs was higher (0.858, 95% confidence interval (CI) 0.830-0.883) than sensitivity (0.659, 95% CI 0.594-0.719) by patient. Sensitivities varied by RMA type from 0.492 (95% CI 0.390-0.594, MagicPlex Sepsis Test) to 0.783 (95% CI 0.662-0.870, IRIDICA BAC BSI assay) by patient. Specificities varied more by patient population, ranging from 0.811 (95% CI 0.716-0.879) in the intensive care population to 0.892 (95% CI 0.838-0.930) in the emergency department population, by patient. Similar metrics were observed when the analysis was done by sample. Risk of bias was judged to be high in all included articles. INTERPRETATION: Despite their shorter turnaround time, low sensitivity means RMAs cannot replace BCs. However, our data indicate that RMAs may have value as an add-on test by increasing pathogen detection rates. Higher-sensitivity RMAs are needed which could possibly be achieved by expanding pathogen coverage and increasing blood sample volumes. High-quality implementation studies and standardized reporting are required to assess the clinical advantages of RMAs. FUNDING: Centre for Translational Medicine, Semmelweis University.
2. Dynamic changes in peripheral blood lymphocyte trajectory predict the clinical outcomes of sepsis.
Using latent class mixed models on longitudinal lymphocyte counts, four trajectory phenotypes were identified and externally validated; the high-declining phenotype carried the highest 28-day mortality (~26%). A nomogram incorporating trajectory class and immune subsets provided individualized mortality risk estimates.
Impact: Introduces validated dynamic immunophenotypes with clear prognostic value, moving beyond static counts toward precision risk stratification and immunotherapy selection.
Clinical Implications: Incorporating serial lymphocyte trajectories and subsets can refine mortality risk assessment and identify candidates for immune-targeted therapies or immunoadjuvant trials.
Key Findings
- Identified four longitudinal lymphocyte trajectory phenotypes (α high-declining, β stable-medium, γ high-increasing, δ stable-low) across retrospective (n=2,149) and validation (n=2,388) cohorts.
- The α (high-declining) phenotype had the highest severity and 28-day mortality (25.9%) in both cohorts.
- A multivariable model and nomogram using age, APACHE II, heart rate, NK cell count, infection source, and trajectory phenotype independently predicted 28-day mortality.
Methodological Strengths
- Large multi-cohort design with external validation and a prospective cohort
- Advanced latent class mixed modeling on longitudinal data with immune subset profiling
Limitations
- Observational design limits causal inference and may be affected by measurement frequency and clinical practice variability
- Generalizability may vary across institutions and resource settings
Future Directions: Prospective interventional trials to test immunotherapy selection guided by trajectory phenotypes; integration with other omics (e.g., cytokines, transcriptomics) for multi-modal risk models.
BACKGROUND: Sepsis induces profound derangements in the immune system, including lymphopenia, which correlates with immunosuppression and poor prognosis. However, most evaluations of immunosuppression in sepsis patients rely on static, sporadic lymphocyte counts, lacking dynamic modeling over the disease course. This study aimed to apply latent class mixed modeling on longitudinal lymphocyte counts to uncover heterogeneous trajectory phenotypes in sepsis patients and assess their predictive value for clinical outcomes. RESULTS: Four lymphocyte trajectory phenotypes were identified in the retrospective cohort (n=2,149) and externally validated (n=2,388): high-declining (α, 3.8%), stable-medium (β, 69.3%), high-increasing (γ, 3.2%), and stable-low (δ, 23.8%). The α phenotype exhibited the highest disease severity and mortality (25.9%) compared with other phenotypes in both cohorts. In the prospective cohort (n=1,056), all lymphocyte subset counts differed among phenotypes on admission (P <.001) and were lower in non-survivors (P<.05). Multivariable regression demonstrated that age, Acute Physiology and Chronic Health Evaluation-II score, heart rate, natural killer cell count, infection source, and lymphocyte trajectory phenotype were independent predictors of 28-day mortality. A nomogram combining these variables provided individualized risk estimations. CONCLUSIONS: The lymphocyte trajectories delineated novel dynamic phenotypes associated with divergent sepsis outcomes. Incorporating longitudinal trajectory modeling and lymphocyte subsets may improve prognostic risk assessment and guide the selection of immunotherapies tailored to specific immune phenotypes in sepsis patients. CLINICAL TRIAL REGISTRATION: https://www.chictr.org.cn/showproj.aspx?proj=18277, identifier ChiCTR-40 ROC-17010750.
3. Lactated Ringer's or Normal Saline for Initial Fluid Resuscitation in Sepsis-Induced Hypotension.
In this secondary analysis of CLOVERS (n=1,563), initial resuscitation with lactated Ringer’s was associated with lower 90-day mortality (adjusted HR 0.71) and more hospital-free days versus 0.9% saline. Normal saline was linked to hyperchloremia and lower bicarbonate.
Impact: Addresses a ubiquitous treatment decision with patient-centered outcomes, reinforcing the potential advantage of balanced crystalloids in sepsis-induced hypotension.
Clinical Implications: Prefer balanced crystalloids (e.g., lactated Ringer’s) for initial fluid bolus in sepsis-induced hypotension; avoid large saline loads given metabolic effects and potential mortality signal.
Key Findings
- Among 1,563 CLOVERS participants with sepsis-induced hypotension, lactated Ringer’s was associated with lower 90-day mortality (12.2% vs 15.9%; adjusted HR 0.71, 95% CI 0.51–0.99; p=0.043).
- Lactated Ringer’s recipients had more 28-day hospital-free days (adjusted mean difference 1.6 days; p=0.009).
- Normal saline was associated with higher serum chloride and lower bicarbonate levels, consistent with hyperchloremic acidosis.
Methodological Strengths
- Large multicenter dataset from a randomized trial framework with prespecified outcomes
- Adjusted analyses comparing predominant pre-randomization fluid types
Limitations
- Non-randomized allocation of the initial fluid type introduces potential confounding despite adjustment
- Secondary analysis; findings hypothesis-generating and limited to U.S. centers
Future Directions: Prospective randomized comparisons of balanced crystalloids versus saline specifically at the earliest resuscitation step; mechanistic studies on chloride load and organ dysfunction.
OBJECTIVES: To assess whether initial fluid resuscitation with lactated Ringer's solution compared with 0.9% saline is associated with improved clinical outcomes in patients with sepsis-induced hypotension. DESIGN: Secondary analysis of the randomized controlled Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis (CLOVERS) trial. SETTING: ICUs and emergency departments in 60 U.S. centers from March 2018 to January 2022. PATIENTS: Participants from the CLOVERS trial. Adult patients with a suspected or confirmed infection and hypotension caused by sepsis. INTERVENTIONS: Participants received 1-3 L of crystalloid fluid for initial fluid resuscitation before randomization. In this analysis, participants were categorized into a lactated Ringer's group and a 0.9% saline group based on the fluid type predominantly used for the initial fluid resuscitation (i.e., ≥ 95% of pre-randomization fluid). MEASUREMENTS AND MAIN RESULTS: Of 1563 participants with sepsis-induced hypotension included in the CLOVERS trial, 622 (39.8%) received lactated Ringer's solution and 690 (44.1%) received 0.9% saline as solution for the initial fluid bolus. Death before discharge home by day 90 occurred in 76 of 622 participants (12.2%) in the lactated Ringer's group and in 110 of 690 participants (15.9%) in the 0.9% saline group, resulting in an adjusted hazard ratio of 0.71 (95% CI, 0.51-0.99; p = 0.043). Patients receiving lactated Ringer's solution had more hospital-free days at 28 days than those receiving 0.9% saline (16.6 ± 10.8 vs. 15.4 ± 11.4, respectively; adjusted mean difference, 1.6 d [95% CI, 0.4-2.8 d; p = 0.009]). Treatment with 0.9% saline was associated with higher levels of serum chloride and decreased levels of serum bicarbonate. CONCLUSIONS: Initial fluid resuscitation with lactated Ringer's solution, compared with 0.9% saline, might be associated with improved survival in patients with sepsis-induced hypotension.